!Objective: In patients with malignant effusions and ECOG 3 -4 or unexpandable lung, the PleurX ® catheter system provides an effective at-home palliation of symptoms associated with recurrent pleural effusions. We investigated the clinical results of patients treated by this method in our population. Methods: All patients treated with PleurX between June 2005 and September 2010 in our clinical center were recorded using a predefined data sheet. Primary points of interest were complications associated with the insertion procedure, short-and long-term complications after insertion of the catheter, the rate of pleurodesis, the frequency of hospitalizations due to effusionassociated symptoms, time of drainage and survival time after insertion. In order to assess follow-up, a standardized questionnaire was sent to the attending practitioners. Results: Pleural effusions were most frequently due to lung cancer, breast cancer and mesothelioma. The rate of compilations associated with the insertion procedure was 7 %, and complications could easily be managed. The rate of short-term complications after insertion of the catheter was 7 %, and of long-term compilations 18 %. The rate of pleurodesis was 16 %. 78 % of patients did not need another hospitalization due to effusionrelated symptoms. The mean time of drainage was 52 days. The mean survival after insertion of the drainage was 76 ± 85 days (1 -453). Conclusions: The insertion of a PleurX catheter is associated with a low complication rate. Shortterm and long-term complications are usually mild and can be readily managed. Hospitalizations due to effusion-related symptoms were not necessary in the majority of patients.Dieses Dokument wurde zum persönlichen Gebrauch heruntergeladen. Vervielfältigung nur mit Zustimmung des Verlages. Einleitung
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.